A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study with an Open-Label Extension to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Preventive Treatment of Menstrual Migraine

Principal Investigator

Alexandre Mathy

Contact us

Email: dendron@ouh.nhs.uk

IRAS number

1010933